![Jean-Marie Cuillerot](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Jean-Marie Cuillerot formerly worked at Agenus, Inc., as Chief Medical Officer from 2017 to 2018, EMD Serono Research & Development Institute, Inc., as Vice President-Clinical Immunotherapy, and Acrivon Therapeutics, Inc., as Chief Medical Officer from 2024 to 2025.
Dr. Cuillerot received his undergraduate degree, graduate degree, and doctorate degree from the University of Strasbourg.
Anciens postes connus de Jean-Marie Cuillerot
| Sociétés | Poste | Fin |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 09/04/2025 |
| AGENUS INC. | Directeur Technique/Scientifique/R&D | 17/01/2018 |
EMD Serono Research & Development Institute, Inc. | Corporate Officer/Principal | - |
Formation de Jean-Marie Cuillerot
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
12
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Agenus, Inc.
 Agenus, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of technologies to treat cancers and infectious diseases | Health Technology |
University of Strasbourg
 University of Strasbourg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono Research & Development Institute, Inc. | |
Acrivon Therapeutics, Inc.
 Acrivon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops and sells precision oncology medicines | Health Technology |
